drugset / Trial / NCT07389278
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open label, intra-patient dose escalation, to evaluate ADI-PEG 20, in combination with Temozolomide (TMZ) and radiation therapy (RT) in children, adolescents and young adult patients with newly diagnosed high grade glioma (HGG).
Timeline
- Start
- 2026-03-09
- Primary completion
- 2032-06-30
- Completion
- 2035-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegargiminase | Protein / enzyme biologic | 36 mg/m2 | Intramuscular |
| Background | Temozolomide | Small molecule | — | Oral |